Trial Profile
A phase II trial of oxipurinol in autosomal dominant polycystic kidney disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2018
Price :
$35
*
At a glance
- Drugs Oxipurinol (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Proof of concept; Therapeutic Use
- 13 Aug 2018 According to a XORTX Therapeutics media release, the company with its collaborative partner, Cato Clinical Research, has filed its pre-IND meeting documents with the FDA. The meeting with the FDA has been scheduled for September 20, 2018.
- 28 Jun 2018 According to a XORTX Therapeutics media release, the company has collaboration with The Polycystic Kidney Disease Foundation fo this trial.
- 08 Jun 2018 According to a XORTX Therapeutics media release, has filed its pre-IND meeting request letter with the FDA.The meeting with the FDA has been scheduled for September 10, 2018.